United States Patent 4,211,771: Ribavirin Method-of-Use Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 4,211,771 covers human antiviral treatment methods using 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, now known as ribavirin. The patent claims administration of ribavirin for broad viral diseases, specified virus families, particular diseases, dose ranges, concentrations, and routes of administration. It is an expired patent and does not currently block generic ribavirin manufacture, sale, or use in the United States.

The patent was strategically important because it moved ribavirin protection beyond the chemical compound itself and into therapeutic use. Its claims reached hepatitis, influenza, herpes infections, measles, poxvirus infections, paramyxovirus infections, and other viral diseases. The claims were method-of-treatment claims, not claims to the ribavirin molecule, a commercial formulation, or a manufacturing process. [1]

What drug does U.S. Patent 4,211,771 protect?

The patent protects therapeutic use of ribavirin, a synthetic nucleoside analogue also known as:

1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
Ribavirin
Virazole active ingredient
Rebetol active ingredient
Copegus active ingredient

Ribavirin has broad antiviral activity but is generally used in combination regimens or for specific respiratory indications rather than as a universal antiviral monotherapy. FDA-approved uses have included inhaled treatment for respiratory syncytial virus infection and oral treatment in combination with interferon-based regimens for chronic hepatitis C. [2][3]

The patent does not claim the chemical structure of ribavirin as such. Earlier compound patents addressed the molecule and related chemical subject matter. U.S. Patent 4,211,771 instead claims processes for administering the compound to human patients.

What are the main claim categories in Patent 4,211,771?

The 20 claims fall into five principal categories.

Claim category	Claims	Core limitation
Broad human antiviral treatment	1	Treating viral disease in humans with an antiviral agent containing ribavirin
Specified virus families	2-6, 8	Poxviruses, herpesviruses, orthomyxoviruses, or paramyxoviruses
Composition concentration and route	7-13	Ribavirin concentration of about 0.01% to 50% by weight and specified administration routes
Hepatitis, influenza, herpes, and measles	14-20	Disease-specific treatment, dose, route, and topical-concentration limitations
Narrow disease and dosage claims	14-20	Approximately 100 to 1,000 mg per day or, for topical use, 0.5% to 5% ribavirin

The claims use the older term “othomyxoviruses,” which appears to be a typographical error for orthomyxoviruses. The intended category is the Orthomyxoviridae family, which includes influenza viruses.

How broad is claim 1?

Claim 1 is the broadest independent claim. It covers:

A process;
Of treating viral diseases;
In human patients;
By administering an antiviral agent;
Having ribavirin as an active component.

The claim does not limit the viral disease to a named virus family, route of administration, formulation, dose, or concentration. On its face, the claim therefore reaches human treatment of viral diseases using a ribavirin-containing antiviral agent.

The principal narrowing features are “human patients” and “active component.” The claim does not cover veterinary treatment. It also requires ribavirin to be an active component of the administered antiviral agent, although it does not necessarily require ribavirin to be the sole active ingredient.

Because the claim is a method claim, infringement would ordinarily require carrying out the claimed treatment method. Manufacturing ribavirin alone would not infringe claim 1 unless the manufacture or sale were tied to performance of the claimed method under applicable inducement or contributory-infringement standards.

What virus families are covered by claims 2 through 6?

Claim 2 limits claim 1 to viral diseases caused by four virus families:

Poxviruses
Herpesviruses
Orthomyxoviruses
Paramyxoviruses

Claims 3 through 6 separately narrow claim 2 to each family.

Claim	Virus category
2	Poxviruses, herpesviruses, orthomyxoviruses, or paramyxoviruses
3	Poxviruses
4	Herpesviruses
5	Orthomyxoviruses
6	Paramyxoviruses

The family-level language is broader than a claim directed only to a named disease. For example, claim 4 is not limited to herpes labialis or herpes zoster. Those diseases are separately recited in claim 17.

The practical value of these claims was greatest during the patent term, when ribavirin was being evaluated across multiple antiviral indications. Their present commercial effect is limited because the patent has expired.

What formulations and administration routes are protected?

Claims 7 and 8 require a composition containing approximately 0.01% to 50% by weight ribavirin.

Claim 7 applies to treatment of viral diseases generally. Claim 8 applies to the four virus families identified in claim 2. The concentration range is broad:

Lower boundary: approximately 0.01% by weight
Upper boundary: 50% by weight

Claims 9 through 13 specify administration routes under claim 8:

Claim	Route
9	Oral
10	Topical
11	Injection
12	Respiratory tract
13	Ophthalmic

These claims do not claim a particular excipient, container, particle size, aerosol device, tablet architecture, cream base, or release profile. They are treatment claims defined principally by the presence and concentration of ribavirin and the administration route.

The respiratory-tract claim is particularly relevant to inhaled ribavirin products such as Virazole. The patent itself, however, does not establish exclusivity over every inhalation device or every aerosol formulation. Later patents could have claimed specific delivery systems, aerosol-generation technology, formulation parameters, or manufacturing processes.

What diseases and doses are covered by claims 14 through 20?

Claims 14 through 20 address specific clinical indications.

Claim	Disease or indication	Dose or formulation limitation	Route
14	Viral hepatitis	Approximately 100-1,000 mg total daily	Oral preparation
15	Influenza	Approximately 100-1,000 mg total daily	Not independently limited
16	Influenza	Approximately 100-1,000 mg total daily	Oral
17	Herpes labialis, herpes progenitalis, herpes zoster, herpes gingivostomatitis	Ribavirin-containing composition	Not independently limited
18	Same herpes indications	Approximately 100-1,000 mg total daily	Oral
19	Same herpes indications	Approximately 0.5%-5% ribavirin	Topical
20	Measles	Approximately 100-1,000 mg total daily	Not independently limited

Claim 14 is important because it reaches oral ribavirin treatment of viral hepatitis. That subject matter later became commercially significant in hepatitis C treatment, although the modern clinical use of ribavirin developed through later regulatory approvals, combination regimens, labeling, and additional intellectual property.

Claim 19 is directed to topical treatment of specified herpes infections using a relatively narrow 0.5%-5% concentration range. It does not claim every topical antiviral cream or every topical herpes treatment.

When did U.S. Patent 4,211,771 expire?

U.S. Patent 4,211,771 issued on July 8, 1980. Because it is a pre-1995 U.S. patent, its ordinary term was generally calculated as 17 years from issuance, subject to any applicable terminal disclaimer, patent-term adjustment, or other statutory modification. Its ordinary expiration date was therefore July 8, 1997. [1][4]

Event	Date
Patent issued	July 8, 1980
Ordinary 17-year expiration	July 8, 1997
Current status	Expired

No current U.S. exclusivity should be attributed to Patent 4,211,771. A party assessing freedom to operate should distinguish this expired patent from later patents covering particular ribavirin products, combinations, formulations, manufacturing methods, or delivery systems.

What was the relationship between the patent and ribavirin’s later commercial products?

Ribavirin reached the market through multiple product and indication pathways.

Product or use	Company historically associated with product	General regulatory role
Virazole inhalation solution	ICN Pharmaceuticals and successor commercial entities	Inhaled treatment for severe RSV infection in appropriate pediatric patients
Rebetol capsules and oral solution	Schering-Plough, later Merck	Oral ribavirin used with interferon-based hepatitis C regimens
Copegus tablets	Roche	Oral ribavirin used with peginterferon alfa-based hepatitis C regimens
Generic ribavirin	Multiple manufacturers	Oral capsules, tablets, oral solution, and other approved presentations

The product patents and regulatory exclusivities associated with these products were separate from Patent 4,211,771. The 1980 patent did not itself create permanent exclusivity over Rebetol, Copegus, or Virazole.

What is the Orange Book status of ribavirin?

The Orange Book lists approved drug products and patent information submitted by sponsors for qualifying products. Patent 4,211,771 is expired and should not be treated as a live Orange Book barrier.

Ribavirin’s regulatory history includes different approved dosage forms and indications. Orange Book analysis must therefore be conducted at the product level, including:

Approved application;
Dosage form;
Strength;
Reference listed drug;
Listed patents;
Pediatric exclusivity;
Regulatory exclusivity;
Current marketing status.

A generic applicant challenging a live listed patent would normally use an Abbreviated New Drug Application certification under Paragraph I, II, III, or IV of the Hatch-Waxman statute. Patent 4,211,771 no longer creates a Paragraph IV barrier because its term has expired. [5]

Are there current Paragraph IV challenges based on Patent 4,211,771?

No current Paragraph IV challenge can create a valid infringement dispute based solely on an expired patent. A Paragraph IV certification may historically have been relevant to ribavirin products when later patents remained listed, but the expired 1980 patent cannot support an injunction against present generic entry.

For ribavirin, the commercially relevant patent questions historically centered on later product, formulation, combination, or use patents rather than the expired foundational method claims. The timing and effect of any Paragraph IV filing would depend on the specific reference listed drug and the patent numbers listed for that drug.

What later patent subject matter could still affect ribavirin?

The principal residual patent risks historically associated with ribavirin fell into five groups.

Formulation patents

These could cover:

Aerosolized ribavirin;
Respiratory delivery systems;
Stabilized solutions;
Oral liquid formulations;
Controlled-release dosage forms;
Specific excipient combinations;
Particle-size or nebulization parameters.

Patent 4,211,771 does not claim these technical features in detail.

Combination-treatment patents

Later patents addressed ribavirin in combination with interferons and other antiviral agents. Combination claims could cover:

Ribavirin plus interferon alfa;
Ribavirin plus pegylated interferon;
Dose schedules;
Treatment durations;
Patient-response criteria;
Genotype-specific therapy.

These later claims became important during the hepatitis C treatment era.

Method-of-use patents

Later use patents could be narrower than Patent 4,211,771 and focus on:

Chronic hepatitis C;
Specific viral genotypes;
Relapsed or nonresponsive patients;
Combination regimens;
Particular treatment durations;
Use with direct-acting antivirals.

The broad hepatitis and influenza language in claim 14 and claim 15 did not prevent later parties from seeking narrower protection for new regimens.

Manufacturing patents

Ribavirin manufacturing patents could cover:

Glycosylation of the triazole carboxamide base;
Protection and deprotection steps;
Crystallization;
Polymorph control;
Impurity reduction;
Starting-material preparation;
Scale-up processes.

These rights could affect suppliers even after the expiration of the original compound and method patents.

Regulatory and product-specific rights

FDA exclusivity, pediatric exclusivity, orphan-drug exclusivity, and product-specific labeling restrictions could delay competition independently of Patent 4,211,771. These rights are time-limited and must be analyzed separately from patent term.

Which companies challenged or commercialized ribavirin products?

The principal commercial participants have included ICN Pharmaceuticals, Schering-Plough, Merck, Roche, Valeant and generic manufacturers. The competitive structure changed substantially after direct-acting antiviral regimens reduced the role of interferon and ribavirin in hepatitis C treatment.

The relevant business issue is no longer broad molecule exclusivity. It is the size of the remaining approved market, the indication-specific label, supply economics, and any residual product or manufacturing rights. Inhaled ribavirin and certain combination uses have had different commercial profiles from generic oral ribavirin.

How strong is the patent estate for ribavirin?

The original ribavirin estate was strong during the 1970s and 1980s because it combined:

Chemical compound protection;
Broad antiviral method claims;
Virus-family claims;
Formulation-concentration claims;
Disease-specific claims;
Route-of-administration claims.

That estate is no longer a live U.S. exclusivity barrier. The core compound and broad method claims are expired. Any current patent strength would have to come from later, narrower rights directed to a particular formulation, combination, manufacturing process, or newly defined treatment population.

Estate component	Current strategic position
Ribavirin compound patent	Expired
Patent 4,211,771 broad treatment claims	Expired
Broad virus-family claims	Expired
Oral and topical dose claims	Expired
Inhalation-related subject matter	Requires separate later-patent review
Combination therapy claims	Requires product- and indication-specific review
Manufacturing patents	Requires process-specific review
FDA exclusivity	Product- and approval-specific, generally time-limited

What generic launch risks exist for ribavirin?

For standard oral ribavirin, the primary generic-entry risks are commercial and regulatory rather than based on Patent 4,211,771.

Potential launch issues include:

Bioequivalence requirements;
Product-specific labeling;
Pregnancy and teratogenicity warnings;
Pharmacokinetic differences;
Oral-solution formulation requirements;
Supply of pharmaceutical-grade ribavirin;
Any currently listed later patents;
State substitution rules;
Declining demand after the shift to interferon-free hepatitis C regimens.

A generic manufacturer would not ordinarily face a valid infringement injunction based on the 1980 patent. The risk assessment must instead focus on live Orange Book patents, FDA exclusivity, formulation complexity, and market size.

What patent litigation and settlement issues matter?

The historical ribavirin disputes were more likely to involve later product and combination patents than Patent 4,211,771 itself. A settlement analysis should examine:

The specific patent numbers asserted;
The asserted claims;
Filing and settlement dates;
Authorized-generic provisions;
Launch dates;
License territory;
Royalty obligations;
Product-label restrictions;
Whether the settlement involved an agreement with a first filer.

Patent 4,211,771 cannot support a present-day exclusionary settlement because it expired in 1997. Any current dispute tied to ribavirin must rely on a later patent or a non-patent regulatory right.

How does Patent 4,211,771 compare with later ribavirin patents?

Patent 4,211,771 is broad in therapeutic concept but relatively limited in technical detail. It claims the use of ribavirin across diseases, virus families, doses, concentrations, and routes.

Later patents generally pursued narrower but more commercially specific subject matter:

Patent 4,211,771	Later ribavirin patents
Broad antiviral treatment	Specific clinical regimen
General virus families	Defined virus, genotype, or patient group
Broad concentration range	Specific formulation or excipient
General administration routes	Defined device or delivery parameters
100-1,000 mg daily claims	Precise dosing schedule and duration
Broad historical indications	Label-linked commercial use

The 1980 patent had substantial historical breadth, but breadth does not preserve exclusivity after expiration.

Key Takeaways

U.S. Patent 4,211,771 covers human treatment methods using ribavirin.
The claims cover broad viral diseases, four virus families, hepatitis, influenza, herpes infections, and measles.
The patent also claims oral, topical, injectable, respiratory, and ophthalmic administration.
Claims 14 through 20 include a 100-1,000 mg daily dose range and a 0.5%-5% topical concentration range.
The patent issued on July 8, 1980, and its ordinary term expired on July 8, 1997.
It does not currently block generic ribavirin manufacture, sale, or use in the United States.
Current risks must be evaluated through later formulation, combination, manufacturing, Orange Book, and regulatory rights.
Ribavirin’s commercial landscape includes Virazole, Rebetol, Copegus, and generic products.
The patent is historically important but has no current standalone exclusionary value.

Frequently Asked Questions

Does U.S. Patent 4,211,771 cover ribavirin itself?

No. It covers methods of treating human viral diseases by administering an agent containing ribavirin. The molecule itself was addressed in separate compound patenting.

Can a company sell generic ribavirin after Patent 4,211,771 expired?

Yes, subject to FDA approval, applicable live patents, product-specific regulatory requirements, and other legal requirements. The expired patent alone does not prevent generic entry.

Does the patent cover hepatitis C treatment?

Claim 14 broadly covers oral ribavirin treatment of viral hepatitis. The claim does not expressly name hepatitis C, and it expired in 1997. Later hepatitis C combination patents and regulatory approvals were separate matters.

Does claim 19 cover every topical herpes product containing ribavirin?

No. Claim 19 is limited to treatment of the specified herpes conditions using a topical composition containing approximately 0.5%-5% ribavirin. It is also expired.

Does the patent cover veterinary antiviral treatment?

No. The claims expressly require treatment of human patients. Veterinary treatment is outside the literal human-patient limitation, although other patents or legal theories could be relevant.

References

U.S. Patent No. 4,211,771. (1980). Method for treating viral diseases. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2002). Rebetol (ribavirin) prescribing information. FDA.
U.S. Food and Drug Administration. (2011). Virazole (ribavirin) inhalation solution prescribing information. FDA.
United States Code, 35 U.S.C. § 154. Patent term provisions.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	199463	⤷ Start Trial
Argentina	205339	⤷ Start Trial
Argentina	207138	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,211,771

Summary for Patent: 4,211,771